Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 940-783-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 06 August 2013 - 23 August 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was performed according to OECD guidelines and GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- 1,15-dichloro-3,5,8,11,13-pentaoxapentadecane; 1-chloro-2-[(2-chloroethoxy)methoxy]ethane; 1-chloro-2-{[2-(2-chloroethoxy)ethoxy]methoxy}ethane
- EC Number:
- 940-783-4
- Molecular formula:
- C5H10Cl2O2 C10H20Cl2O5 C7H14Cl2O3
- IUPAC Name:
- 1,15-dichloro-3,5,8,11,13-pentaoxapentadecane; 1-chloro-2-[(2-chloroethoxy)methoxy]ethane; 1-chloro-2-{[2-(2-chloroethoxy)ethoxy]methoxy}ethane
- Test material form:
- other: liquid
- Details on test material:
- Name: PREPOLYMER D
Chemical Name: Reaction mass of Bis (2-chloroethoxy)methane and 1,15-dichloro-3,5,8,11,13-pentaoxa-pentadecane and 1-(2-chloroethoxy)-2-(2-chloroethoxymethoxy)ethane
Batch/Lot Number: 030613
Purity: 100% (multi constituent substance)
Appearance: slightly brownish liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: RccHan:WIST
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species and strain: RccHan:WIST rats
Source: Harlan Laboratories S.r.l.
S.Pietro al Natisone (UD), Zona Industriale Azzida, 57 33040, Italy
Hygienic level at arrival: SPF
Hygienic level during
the study: Standard housing conditions
Number of animals: 12 animals,
Sex: Female, nulliparous and non-pregnant.
Age of animals at dosing: Young healthy adult rats, ~9 weeks old
Date of receipt: 24 July 2013
Body weight at treatment: 168 – 200 g
Acclimation period: 13, 14, 15, 16 days
Animal health: Only healthy animals were used for the test. The veterinarian certified health status.
Number of animal room: 522/5
Housing: 3 animals / group
Cage type: Type II polypropylene/polycarbonate
Bedding: Lignocel Bedding for Laboratory Animals was available to animals during the study.
A copy of the Certificate of Analysis is retained in the archive at CiToxLAB Hungary Ltd.
Lighting period: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature: 22 ± 3 °C
Relative humidity: 35 - 76 %
Ventilation: 15-20 air exchanges/hour
Enrichment: Animals were housed by group to allow social interaction and with deep wood sawdust bedding to allow digging and other normal rodent activities.
The temperature and relative humidity were recorded twice daily during the study.
Animals received ssniff® SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance" produced by ssniff Spezialdiäten GmbH, D-59494 Soest Germany ad libitum, and tap water from the municipal supply, as for human consumption from 500 ml bottle ad libitum. The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- A single oral gavage administration was followed by a fourteen-day observation period. On the day before treatment, the animals were fasted. The food but not water was withheld during an overnight period. Animals were weighed just before treatment. The test item was administered by oral gavage in the morning. The food was returned 3 hours after the treatment.
- Doses:
- Initially, three females assigned to (Group 1) were treated at a dose level of 2000 mg/kg bw. The test item caused mortality in this group (3/3). Therefore, a second group (Group 2) was treated at a dose level of 300 mg/kg bw.
The second group of three females (Group 2) was treated at a dose level of 300 mg/kg bw. The test item caused mortality in this group (2/3). Therefore, a third group (Group 3) was treated at a dose level of 50 mg/kg bw.
The third group of three females (Group 3) was treated at a dose level of 50 mg/kg bw. The test item did not cause mortality in this group; therefore a confirmatory group of three females (Group 4) was treated at the same dose level. The test item did not cause mortality in the confirmatory group, so no further testing was required according to OECD 423 and Commission Regulation (EC) NO 440/2008 of 30 May 2008, B.1.Tris. - No. of animals per sex per dose:
- 3 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations were performed on the surviving animals at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter. Individual observations were performed on the skin, fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. The body weight was recorded on the day before treatment (Day -1), on the day of the treatment (Day 0) and weekly after. Moreover, the body weight of found dead animals was recorded at necropsy.
- Necropsy of survivors performed: yes
- Other examinations performed: None - Statistics:
- None
Results and discussion
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- >= 30 - <= 300 mg/kg bw
- Based on:
- test mat.
- Mortality:
- PREPOLYMER D caused mortality at the dose level of 2000 mg/kg bw (3/3) three to six hours after administration and at the dose level of 300 mg/kg bw (2/3) 1 day after administration.
- Clinical signs:
- other: Treatment with PREPOLYMER D at the dose level of 2000 mg/kg bw caused decreased activity (3/3), hunched back (1/3), prone position (3/3), and death (3/3). Treatment with PREPOLYMER D at dose level 300 mg/kg bw caused decreased activity (3/3), excessive di
- Gross pathology:
- Diffuse red discoloration of the glandular stomach observed in 3/3 found dead animals dosed at 2000 mg/kg bw was considered to be associated with administration of the test item.
Other changes such as dark/red discoloration of the non-collapsed/collapsed lungs, foamy white material in the trachea or red liquid at the perinasal fur were regarded as agonal or post mortem dosed at 2000 and 300 mg/kg bw.
No macroscopic observations were seen in animals dosed at 50 mg/kg bw and terminated on Day 14.
Also, no gross changes were noted in one surviving rat dosed at 300 mg/kg bw and necropsied on Day 14.
Applicant's summary and conclusion
- Interpretation of results:
- Toxicity Category III
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- PREPOLYMER D was found to be between 50 and 300 mg/kg bw in female RccHan:WIST rats.
- Executive summary:
The single-dose oral toxicity of the test substance was performed according to the acute toxic class method (OECD 423 and Commission Regulation (EC) NO 440/2008 of 30 May 2008, B.1.Tris) in RccHan:WIST rats.
The test substance was administered in PEG 400 at concentrations of 200, 30 and 5 mg/mL with a dosing volume of 10 mL/kg bw.
A single oral treatment was carried out by gavage for each animal after an overnight food withdrawal. Food was made available again 3 hours after the treatment.
Dose at 2000 mg/kg bw (Group 1):
Initially, three females assigned to (Group 1) were treated at a dose level of 2000 mg/kg bw. The test item caused mortality in this group (3/3). Therefore, a second group (Group 2) was treated at a dose level of 300 mg/kg bw.
Dose at 300 mg/kg bw (Group 2):
The second group of three females (Group 2) was treated at a dose level of 300 mg/kg bw. The test item caused mortality in this group (2/3). Therefore, a third group (Group 3) was treated at a dose level of 50 mg/kg bw.
Dose at 50 mg/kg bw (Group 3 and Group 4):
The third group of three females (Group 3) was treated at a dose level of 50 mg/kg bw. The test item did not cause mortality in this group; therefore a confirmatory group of three females (Group 4) was treated at the same dose level. The test item did not cause mortality in the confirmatory group, so no further testing was required according to OECD 423 and Commission Regulation (EC) NO 440/2008 of 30 May 2008, B.1.Tris.
Clinical observations were performed on the surviving animals at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter. Body weight was measured on Days -1, 0 and 7 and before necropsy. All animals were subjected to a necropsy and a macroscopic examination.
Results
Mortality
The test substance caused mortality at the dose level of 2000 mg/kg bw (3/3) and at the dose level of 300 mg/kg bw (2/3).
Clinical observations
Treatment at the dose level of 2000 mg/kg bw caused decreased activity (3/3), hunched back (1/3), prone position (3/3), and death (3/3).
Treatment at dose level 300 mg/kg bw caused decreased activity (3/3), excessive digging (2/3), hunched back (3/3), prone position (1/3), piloerection (3/3), and death (2/3).
Treatment at dose level 50 mg/kg bw caused faeces liquid (3/6).
Body weight and body weight gain
Body weight gains of treated animals during the study showed no indication of a treatment-related effect on the surviving animals at the dose level of 300 and 50 mg/kg bw.
Macroscopic Findings
Diffuse red discoloration of the glandular stomach observed in 3/3 found dead animals dosed at 2000 mg/kg bw was considered to be associated with administration of the test item.
Other changes such as dark/red discoloration of the non-collapsed/collapsed lungs, foamy white material in the trachea or red liquid at the perinasal fur were regarded as agonal or post mortem dosed at 2000 and 300 mg/kg bw.
No macroscopic observations were seen in animals dosed at 50 mg/kg bw and terminated on Day 14.
Also, no gross changes were noted in one surviving rat dosed at 300 mg/kg bw and necropsied on Day 14.
Conclusion:
The test substance was found to be between 50 and 300 mg/kg bw in female RccHan:WIST rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
